目的 探讨采用澳泰乐颗粒联合拉米夫定治疗慢性乙型肝炎的临床疗效。方法 选择2020年6月—2021年6月在解放军联勤保障部队第九八八医院诊治的88例慢性乙型肝炎患者，随机分为对照组和治疗组，每组各44例。对照组口服拉米夫定片，0.1 g/次，1次/d。治疗组在对照组的基础上口服澳泰乐颗粒，1袋/次，3次/d。两组治疗24周。观察两组患者临床疗效，比较治疗前后两组患者症状好转时间，肝功能指标丙氨酸氨基转氨酶（ALT）、谷氨酸转肽酶（GGT）、总胆红素（TBIL）、天门冬氨酸氨基转移酶（AST），血清因子γ干扰素（INF-γ）、白细胞介素-4（IL-4）、转化生长因子-β1（TGF-β1）和白细胞介素-6（IL-6）水平，及不良反应情况。结果 治疗后，治疗组总有效率明显高于对照组（97.73%vs 79.55%，P<0.05）。治疗后，治疗组症状好转时间均明显早于对照组（P<0.05）。治疗后，两组肝功能ALT、AST、GGT、TBIL指标明显下降（P<0.05），且治疗组肝功能指标水平明显低于对照组（P<0.05）。治疗后，两组血清因子IL-6、TGF-β1水平明显下降，而IL-4和IFN-γ水平明显升高（P<0.05），且治疗组血清因子水平均明显好于对照组（P<0.05）。治疗组不良反应发生率为6.81%，明显低于对照组的18.18%（P<0.05）。结论 澳泰乐颗粒联合拉米夫定治疗慢性乙型肝炎能使患者症状明显好转，改善肝功能，降低炎症反应。

Objective To investigate the efficacy of Aotaile Granules combined with lamivudine in treatment of hepatitis B. Methods Patients (88 cases) with hepatitis B in the 988 Hospital of the PLA Joint Logistics Support Force from June 2020 to June 2021 were randomly divided into control and treatment group, and each group had 44 cases. Patients in the control group were po administered with Lamivudine Tablets, 0.1 g/time, once daily. Patients in the treatment group were po administered with Aotaile Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 24 weeks. After treatment, the clinical evaluation was evaluated, the improvement time of symptom, the liver function index ALT, AST, GGT and TBIL, and the levels of serum factors IL-6, TGF-β, IL-4 and IFN-γ, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (97.73% vs 79.55%, P < 0.05). After treatment, the improvement time of symptom in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the indexes of liver function ALT, AST, GGT and TBIL in two groups were significantly decreased (P < 0.05), and the liver function in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the levels of serum factors IL-6 and TGF-β1 in two groups were significantly decreased, while the levels of IL-4 and IFN-γ were significantly increased (P < 0.05), and the levels of serum factors in the treatment group were significantly better than those in the control group (P < 0.05). The incidence of adverse reactions in the treatment group was 6.81%, which was significantly lower than 18.18% in the control group (P < 0.05). Conclusion The combination of lamivudine and Aotaile Granules can significantly improve the symptoms of patients, enhance liver function, and reduce inflammatory response.

R977